AI-driven genomics leader Mapmygenome has announced the strategic acquisition of Microbiome Insights, a Canadian pioneer in microbiome sequencing, in a move designed to strengthen its position in personalized health and microbial research. The acquisition includes Microbiome Insights' CAP-accredited laboratory and valuable intellectual property portfolio, significantly enhancing Mapmygenome's scientific capabilities and global reach.
Strategic Expansion into North American Markets
The acquisition positions Mapmygenome to introduce its integrated genomics and microbiome testing services to North America, providing accessible, data-driven health solutions across international borders. This expansion aligns with the company's strategic vision of growth through targeted acquisitions as it prepares for its listing on the Indian market later this year.
"The human microbiome is pivotal to health, and this acquisition positions us as a leader in this area," said Anu Acharya, Founder and CEO of Mapmygenome. "We gain exceptional expertise in metagenomics, transcriptomics, and targeted metabolomics to serve academic, biotech, and clinical sectors. This accelerates our North American footprint, aligning with our strategic vision of growth through targeted acquisitions leading up to our listing on the Indian market later this year."
Established Research Capabilities
Microbiome Insights brings substantial research experience to the partnership, having completed over 1,000 studies for more than 600 clients globally. The company serves as a trusted partner for academic, clinical, and industrial research sectors. Co-founded by recognized microbiome experts Dr. Brett Finlay, Dr. William Mohn, and Malcolm Kendall, the organization will continue to operate as a premier contract research organization (CRO), supporting innovation in microbial science.
"Joining forces with Mapmygenome provides the resources and capabilities to offer higher quality services to our clients and accelerate growth," said Malcolm Kendall, CEO of Microbiome Insights. "Our combined strengths will deliver a new standard of cutting-edge services for clients worldwide."
Enhanced Service Portfolio
The acquisition enables the combined entity to offer comprehensive services spanning metagenomics, transcriptomics, and targeted metabolomics. This expanded capability portfolio is designed to serve academic, biotech, and clinical sectors with integrated solutions that combine AI-driven genomics expertise with specialized microbiome research capabilities.
The partnership represents a convergence of genomics, microbiome science, and artificial intelligence technologies aimed at advancing global health innovation. While financial terms of the acquisition were not disclosed, the deal marks a significant milestone in the expansion of personalized health solutions across international markets.
